Thoracic spinal cord stimulation improves functional status and relieves symptoms in patients with refractory angina pectoris: the first placebo-controlled randomised study

Eddicks, Stephan; Maier-Hauff, Klaus; Schenk, Michael; Müller, Andreas; Baumann, Gert; Theres, Heinz
May 2007
Heart;May2007, Vol. 93 Issue 5, p585
Academic Journal
Background: Spinal cord stimulation (SCS) is an alternative treatment option for refractory angina. Controlled trials demonstrate symptom relief and improvement in functional status. Since patients experience retrosternal prickling during active SCS, there is no option for blinding patients to active treatment or for placebo control. Objective: To examine the therapeutic effects of subthreshold SCS in patients with refractory angina in a placebo-controlled study. Methods: 12 responders to treatment who had already been treated with SCS for refractory angina were enrolled. Patients were randomised into four consecutive treatment arms, each for 4 weeks, with various stimulation timing and output parameters: 3×2 h/day (phase A) and 24 h/day with conventional output (phase B); 3×2 h/day with a subthreshold output (phase C); and 24 h/day with 0.1 V output, which served as control (phase D). Functional status, quality of life, Canadian Cardiovascular Society classification and nitrate usage were assessed at the end of each 4-week period. Results: In phase D, patients showed a significant reduction in walking distance compared with phases A and C. Canadian Cardiovascular Society classification worsened in phase D compared with phases A-C. Frequency of angina attacks and the visual analogue scale were significantly worse in phase D than in phases A-C. In three patients, it was necessary to prematurely terminate phase D owing to intolerable angina attacks. Conclusions: In this first placebo-controlled trial to apply SCS in patients with refractory angina, improvement in functional status and symptoms was revealed in phases with conventional or subthreshold stimulation, in comparison to a low-output (placebo) phase.


Related Articles

  • Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary Syndrome. Chisholm, Jeffrey W.; Goldfine, Allison B.; Dhalla, Arvinder K.; Braunwald, Eugene; Morrow, David A.; Karwatowska-Prokopczuk, Ewa; Belardinelli, Luiz // Diabetes Care;Jun2010, Vol. 33 Issue 6, p1163 

    OBJECTIVE -- We determined the relationships between glycemia at randomization, concurrent antidiabetic therapy, and change in A1C and fasting plasma glucose (FPG) in patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the...

  • Placebo wins the race. Cohen, Georgiana // Natural Health;Oct99, Vol. 29 Issue 8, p35 

    Reports on the finding that angina patients who received placebo injections of the angina drug vascular endothelial growth factor (VEGF) could walk 44 second longer than those who received low and high doses. Healing effects of the individualized attention and one-on-one care that patients...

  • Plasma levels and vascular effects of endothelin and big endothelin in patients with stable and unstable angina pectoris undergoing coronary bypass grafting Lockowandt, Ulf; Bjessmo, Staffan; Ivert, Torbjörn; Franco-Cereceda, Anders // European Journal of Cardio-Thoracic Surgery;Feb2002, Vol. 21 Issue 2, p218 

    Objectives: The aim of this study was to determine the plasma and pericardial levels of endothelin-1 (ET-1) and its precursor big endothelin-1 (Big ET-1) in patients with unstable and stable angina prior to and following coronary bypass surgery. To further investigate the content of ET-1, tissue...

  • Abnormal origin of the left internal thoracic artery detected only by computed tomography. McMaster, Kelly S.; Blanc, Jean-Michael B.; Hamman, Baron L.; Rosenthal, Robert L. // Baylor University Medical Center Proceedings;Jul2013, Vol. 26 Issue 3, p283 

    The origins of the branches of the subclavian artery are known to be variable. We present the case of a 55-year-old man whose coronary artery bypass surgery necessitated the use of the internal thoracic artery as he lacked other suitable venous conduits. The left internal thoracic artery...

  • Unstable angina pectoris and spinal cord stimulation. Akbas, Mert; Yegin, Arif; Yilmaz, Huseyin; Altekin, R. Emre; Sabit, Muhammed Jamil; Sanli, Suat // Anaesthesia, Pain & Intensive Care;Jul-Sep2015, Vol. 19 Issue 3, p383 

    Angina pectoris is characterized by an oppressive pain in the chest due to inadequate blood flow to the heart muscle. If patients with chronic angina are refractory to conservative therapies and cannot undergo coronary revascularization surgery, spinal cord stimulation can be proposed as a...

  • Towards a better, complete treatment of aortic arch pathologies. De Paulis, Ruggero // European Journal of Cardio-Thoracic Surgery;2017 Supplement, Vol. 51, pi1 

    An introduction is presented in which the editor discusses various reports published within the issue which include the patient management during aortic arch surgery, the early restoration of perfusion as key to prevent spinal cord damage, and the frozen elephant trunk (FET) technique.

  • Patient delay in calling for help: the weakest link in the chain of survival? Penny, W J // Heart;Feb2001, Vol. 85 Issue 2, p121 

    An introduction is presented in which the editor discusses various reports within the issue on topics such as the misconceptions regarding victims of heart attack, the low awareness of angina patients on somatic sensations, and the determinants in cardiovascular disease.

  • Efficacy of Nitroglycerin Patches: Fact or Fancy? Parker, John O. // Annals of Internal Medicine;Apr85, Vol. 102 Issue 4, p548 

    Editorial. Discusses research on the assessment of the efficacy of nitroglycerin patches in the treatment of angina pectoris. Effect of the administration of the patches on a patient's exercise time; Comparison with placebo medication; Issues considered in the administration of nitroglycerin...

  • Effect of Ivabradine, a Novel Antianginal Agent, on Driving Performance. Macher, Jean-Paul; Lévy, Samuel // Clinical Drug Investigation;2009, Vol. 29 Issue 5, p339 

    Background and objective: Ivabradine is a novel pure heart rate-lowering agent that selectively and specifically inhibits pacemaker If current. Ivabradine has been shown to have antianginal and anti-ischaemic properties in patients with stable angina pectoris. Because f channels are also present...


Read the Article


Sign out of this library

Other Topics